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Lung cancer is the leading cause of cancer deaths worldwide. The cytokine interleukin-17A 
supports tumour vascularization and growth, however, its role in lung cancer is unknown. Here 
we show, in the lungs of patients with lung adenocarcinoma, an increase in interleukin-17A 
that is inversely correlated with the expression of T-bet and correlated with the T regulatory 
cell transcription factor Foxp3. Local targeting of interleukin-17A in experimental lung 
adenocarcinoma results in a reduction in tumour load, local expansion of interferon-γ-producing 
CD4 +  T cells and a reduction in lung CD4 + CD25 + Foxp3 +  regulatory T cells. T-bet( − / − ) mice 
have a significantly higher tumour load compared with wild-type mice. This is associated 
with the local upregulation of interleukin-23 and induction of interleukin-17A/interleukin-17R-
expressing T cells infiltrating the tumour. Local anti-interleukin-17A antibody treatment partially 
improves the survival of T-bet( − / − ) mice. These results suggest that local anti-interleukin-17A 
antibody therapy could be considered for the treatment of lung tumours. 
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Lung cancer is the leading cause of cancer deaths worldwide and lung adenocarcinoma is one of the predominant forms1–3. Given the well-established immunosuppressive properties of 
the tumour environment, strategies to reverse these events by stim-
ulating host immune responses are of potential relevance.
Although the role of Th17 cells in autoimmunity has been 
intensively studied4,5, their role in tumour development remains 
largely unknown. Previous reports have shown that both cutaneous 
T-cell lymphomas6 and ovarian carcinomas7 spontaneously secrete 
interleukin (IL)-17A and in a considerable proportion of ovarian 
tumours IL-17A expression correlates with increased vascularity. 
However, no report exists concerning a possible angiogenic role for 
IL-17A in non-small cell lung cancer (NSCLC)8–10. NSCLC cells 
have been reported to produce many angiogenic factors, including 
CXCL8/IL-8 (refs 11,12), which are critically involved in the patho-
genesis of NSCLC13. It has been reported that inhibition of CXCL8 
suppressed the growth of NSCLC in immunodeficient mice14. 
Conversely, tumour-derived CXCL10/interferon (IFN)-inducible 
protein-10 has been identified as an important endogenous angi-
ostatic factor in NSCLC15. As IL-17A induces CXCL8 production 
and CXCL8 is involved in the angiogenic activity of NSCLC16, we 
asked whether IL-17A might be increased and may contribute to 
the development of lung adenocarcinoma. Thus, we analysed the 
role of Th17 cells in a murine model of lung adenocarcinoma and 
human tumours. We identified T-bet as an antagonist of IL-17A/IL-
17R expression that inhibits T regulatory cell development in lung 
tumours. In vivo targeting of IL-17A abrogated tumour growth in 
the presence of T-bet by inhibiting CD4 + CD25 + Foxp3 +  T regula-
tory cells and inducing IFN-γ and tumour necrosis factor-α (TNFα) 
production by CD4 +  T cells. In the absence of T-bet, anti-IL-17A 
antibody therapy inhibited IL-17R expression on CD4 +  and induced 
IFN-γ in lung CD8 +  T cells and improved survival in a murine 
model of lung cancer. Taken together, anti-IL-17A antibody therapy 
emerges as a promising avenue in the treatment of lung cancer.
Results
Expression of ROR transcription factors and IL-17A in 
adenocarcinoma. To address the role of Th17 immune responses 
in tumours, we used quantitative PCR to measure the expression 
of Th17 cell17 lineage-specific transcription factors RORα4 and 
RORC2 (human homologue of mouse RORγt), as well as IL-17A, 
in lung samples derived from patients with lung adenocarcinoma or 
healthy control tissue. The clinical characteristics of the subjects are 
reported in Table 1.
We found that patients with lung adenocarcinoma had a signifi-
cant increase in IL-17A, RORα4 and RORC2 mRNA expression in 
the lung compared with control subjects (Fig. 1a–c, respectively). 
Noteworthy was the tenfold increase in IL-17A mRNA in tumour 
samples suggesting a local induction of Th17 responses at the tran-
scriptional level.
As previous studies had identified T-bet as a negative regulator 
of IL-17A in the lung18, we then investigated whether the increase 
of IL-17A, RORC2 and RORα4 in lung carcinoma was secondary 
to a downregulation of T-bet in the lung tissue. Accordingly, we 
examined correlations between T-bet, IL-17A, RORα4 and RORC2 
expression in tumour samples and healthy control tissues. RORα4 
and RORC2 had higher values when T-bet expression was low 
in normal control lung tissues (Fig. 1d,f, respectively). These data 
Table 1 | Clinical characteristics of the patients used in this human study.
Tissue Cell type Grade T* N† Gender Age (years)
Lung cancer Adenocarcinoma G2 1 2 male 39
Lung cancer Adenocarcinoma G2 2 0 male 51
Lung cancer Adenocarcinoma G2 1 0 male 55
Lung cancer Adenocarcinoma G2 1 0 male 56
Lung cancer Adenocarcinoma G2 2 2 male 58
Lung cancer Adenocarcinoma G2 2 2 male 66
Lung cancer Adenocarcinoma G2 1 1 Female 67
Lung cancer Adenocarcinoma G2–G3 1 2 male 42
Lung cancer Adenocarcinoma G2–G3 3 2 Female 52
Lung cancer Adenocarcinoma G2–G3 3 2 male 54
Lung cancer Adenocarcinoma G2–G3 2 1 Female 54
Lung cancer Adenocarcinoma G2–G3 2 1 male 62
Lung cancer Adenocarcinoma G2–G3 2 0 male 63
Lung cancer Adenocarcinoma G2–G3 2 2 male 70
Lung cancer Adenocarcinoma G3 2 0 male 43
Lung cancer Adenocarcinoma G3 2 0 male 47
Lung cancer Adenocarcinoma G3 2 2 male 48
Lung cancer Adenocarcinoma G3 1 0 male 49
Lung cancer Adenocarcinoma G3 2 2 male 58
Lung cancer Adenocarcinoma G3 1 0 male 61
Lung cancer Adenocarcinoma G3 4 1 male 63
Lung cancer Adenocarcinoma G3 2 0 male 64
Lung cancer Adenocarcinoma G3 2 1 male 68
Lung cancer Adenocarcinoma G3 2 0 Female 69
Lung cancer Adenocarcinoma G3 2 2 male 72
*T: extent of primary tumour.
T1: tumour 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion is more proximal than the lobar bronchus.
T2: tumour more than 3 cm but not more than 7 cm.
T3: tumour more than 7 cm.
T4: tumour of any size that invades any of the following: the mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, oesophagus, vertebral body, carina; separate tumour nodule(s) in a 
different ipsilateral lobe to that of the primary.
†n: regional lymph node metastasis.
n0: no regional lymph node metastasis.
n1: metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension.
n2: metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s).
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indicated a reciprocal inhibitory role of T-bet on RORC2 and 
RORα4 in normal tissue. However, in tumour tissues, these inverse 
correlations were lost, indicating that RORα4 and RORC2 in lung 
tumour expanded independently from T-bet (Fig. 1e,g, respec-
tively). We next analysed the correlation between IL-17A and T-bet 
and found that in control lung tissues T-bet does not decrease when 
IL-17A is increased (Fig. 1h). However, we found an inverse cor-
relation between T-bet and IL-17A expression in tumour samples 
indicating that low values of T-bet occur with high IL-17A expres-
sion in human lung tumours (Fig. 1i).
Increased Foxp3 mRNA transcription in lung adenocarcinoma 
tissue. To understand the potential relationship between Th17 
development and the suppressor regulatory Foxp3 +  CD4 +   
T (Treg) cells in tumour tissues, we next analysed the expression 
of the signature transcription factor of Treg cells, Foxp3, in the 
same human lung tissues where we analysed IL-17A levels. Foxp3 
mRNA expression was significantly increased in lung adenocarci-
noma samples compared with control samples (Fig. 2a). Further-
more, a strong positive correlation was found between Foxp3 and 
RORC2 (Fig. 2b,c) and between Foxp3 and IL-17A mRNA expres-
sion (Fig. 2d,e) in lung adenocarcinoma samples compared with 
control samples. This finding suggests a synergy between Th17 and 
Treg cells in lung adenocarcinoma in the presence of low T-bet 
levels.
T-bet protected mice from lung tumour development. To explore 
the role of T-bet and IL-17A in vivo, we injected L1C2 adenocar-
cinoma cells into T-bet( − / − ) and wild-type mice and found that 
tumour growth was markedly affected in the absence of T-bet19. In 
an initial series of studies, 14 days after tumour cell injection, 50% 
of the lung surface was occupied by a tumour in T-bet( − / − ) mice, 
whereas wild-type controls had less than 10% of lung surface occu-
pied by tumour tissue under the same conditions (Fig. 3a). These 
data extend previous studies on lung metastasis in experimental 
melanoma in T-bet-deficient mice20,21, demonstrating that T-bet 
protects against lung tumour growth.
In an additional approach22, we performed in vivo imaging of 
tumour cells to visualize, monitor and quantify the tumour load 
in the lungs of T-bet( − / − ) and wild-type mice. We used a similar 
model of lung carcinoma where lung tumours were induced by the 
intravenous injection of the luciferase-expressing lung carcinoma 
cell line LL/2-luc-M38. In these studies, we confirmed an increased 
tumour load in the lung of T-bet( − / − ) mice at different time points 
compared with control wild-type mice (Fig. 3b,c). Taken together, 
these data demonstrated that T-bet protects from tumour develop-
ment in experimental lung adenocarcinoma.
T-bet suppressed IL-17A production in CD4 +  T cells in lung 
tumours. Because T-bet inversely correlated with IL-17A in human 
lung adenocarcinoma, we next analysed IL-17A release in the 
supernatants of lung CD4 +  T cells isolated from wild-type and 
T-bet-deficient mice-harbouring tumours. We found a significant 
upregulation of IL-17A production in CD4 +  T cells isolated from 
T-bet( − / − ) mice bearing tumours compared with those isolated 
from wild-type littermates (Fig. 3d). These results indicated that 
the Th17 pathway is expanded in the absence of T-bet in this lung 
adenocarcinoma model.
Local targeting of IL-17A suppressed lung tumour growth. To 
investigate whether Th17 cells are involved in the pathogenesis of 
lung adenocarcinoma, we treated wild-type mice with lung adeno-
carcinoma intranasally with a neutralizing anti-IL-17A antibody 
and analysed tumour development (Fig. 3e). We observed a statisti-
cally significant reduction of tumour growth after intranasal (i.n.) 
treatment of lung tumours with anti-IL-17A antibodies as com-
pared with untreated and IgG-treated mice (Fig. 3f).
Anti-IL-17A antibody treatment partially rescued T-bet( − / − ) 
mice. We then analysed the survival of wild-type and T-bet-deficient 
mice after in vivo i.n. administration of anti-IL-17A antibodies. We 
found that T-bet( − / − ) mice have very low survival rates compared 
with wild-type littermates bearing tumour. At day 19 after tumour 
cell injection, anti-IL-17A antibody treatment rescued all wild-type 
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Figure 1 | Increased expression of Th17 markers in lungs of adenocarcinoma patients. RnA from tumour tissue biopsy samples of patients suffering from 
lung adenocarcinoma and healthy control lung tissues was extracted and analysed by qPCR. mRnA levels of (a) IL-17A (Ncontrol = 9; Nlung carcinoma = 25), 
(b) RoRα4 (Ncontrol = 10; Nlung carcinoma = 25) and (c) RoRC2 (Ncontrol = 10; Nlung carcinoma = 25) are shown. Data are reported as mean values ± s.e.m. 
student’s two-tailed t-test was used. **P,0.01; ***P,0.001. (d) Correlation between T-bet and RoRα4 mRnA expression in control lung tissue (open 
symbols) (N = 10) compared with adenocarcinoma-bearing lung tissue (filled symbols) (e; N = 18), between T-bet and RoRC2 in healthy samples  
(f; N = 10) and carcinoma samples (g; N = 18) and between T-bet and IL-17A in healthy controls (h; N = 9) and adenocarcinoma tissue (i; N = 18).  
Values of individual patients are shown. The correlations are indicated.
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and T-bet-deficient mice bearing tumours. Two days later, however, 
all wild-type mice treated with anti-IL-17 antibody survived, whereas 
only 30% of the T-bet-deficient mice died. We thus concluded that 
T-bet contributes to the survival achieved by anti-IL-17A antibody 
treatment in this model of experimental lung cancer (Fig. 3g).
IL-17A antibody induced IFNγ production by CD4 +  T cells in 
tumours. We then asked whether blockade of IL-17A function 
would favour Th1 cytokine production. We detected a statistically 
significant increase in both IFN-γ (Fig. 3h) and TNFα (Fig. 3i) pro-
tein levels in the supernatants of lung CD4 +  T cells isolated from 
in vivo anti-IL-17A antibody-treated mice bearing tumours, when 
compared with untreated and IgG-treated mice. In addition, in a 
similar model of lung carcinoma, where the Lewis carcinoma cell 
line (LLC1) was injected23, targeted deletion of IL-17A led to induc-
tion of IFN-γ levels in the airways (Fig. 3j) confirming a negative 
regulatory role of IL-17A on IFN-γ production in this lung tumour 
model. We next isolated lung CD4 +  T cells both from untreated 
and tumour-bearing mice and treated these cells either with anti-IL- 
17A or immunoglobulin G (IgG) antibodies for 3 days in vitro  
(Fig. 3k). Interestingly, only CD4 +  T cells isolated from the lungs of 
mice with tumours, that were treated in vitro with anti-IL-17A antibody, 
produced high levels of IFN-γ (Fig. 3k). We thus demonstrate that 
tumour-infiltrating CD4 +  T cells are direct target of anti-IL-17A 
therapy and this treatment favoured the production of IFN-γ by 
lung CD4 +  T cells in experimental lung cancer.
IFN-g production in lung CD8 +  T-bet( − / − ) tumour T cells. We 
next isolated lung CD8 +  T cells from wild-type and T-bet-deficient 
mice bearing tumours treated with anti-IL-17A antibodies. We 
found that lung CD8 +  T cells from T-bet-deficient mice produced 
more IFN-γ protein compared with those isolated from wild-type 
littermates after anti-IL-17A antibody treatment in this lung tumour 
model (Fig. 3l). Moreover, at the RNA level we could show that anti 
IL-17A treatment induced IFN-γ production in lung CD8 +  T cells 
only in T-bet-deficient mice (Fig. 3m). These results indicated a 
T-bet-independent regulation of IFN-γ production in CD8 +  T cells.
Anti-IL-17A antibody reduced IL-6 levels in lung tumours. We 
next analysed the influence of IL-17A on lung cells and tumour cells 
that were used to induce lung tumours (L1C2 and LLC1). In ini-
tial studies we focused on IL-6, a cytokine produced by Th17 cells, 
which inhibits T regulatory cells and induces Th17 cells. As shown 
in Figure 4a,b, in vivo treatment with anti-IL-17A antibodies sig-
nificantly reduced IL-6 production in the airways (broncho-alveolar 
lavage fluid). Furthermore, transforming growth factor (TGF)-β1 
was increased in the supernatants of CD4 +  T cells isolated from 
the lungs of wild-type mice bearing tumours. In addition, decreased 
levels of this cytokine were noted in the supernatants of lung CD4 +  
T cells isolated from anti-IL-17A antibody but not from IgG con-
trol-treated mice, compared with untreated tumour-bearing mice 
(Fig. 4c).
Although no statistical difference in TGF-β release was seen 
between the anti IL-17A antibody and IgG control-treated mice 
(Fig. 4c), TGF-β mRNA expression was upregulated in the lung of 
T-bet-deficient mice compared with wild-type littermates bearing 
tumour (Fig. 4d). Moreover, anti-IL-17A antibody treatment did 
not reduce TGF-β mRNA levels in lung tumour tissue isolated from 
both wild-type and T-bet-deficient mice (Fig. 4d).
Although Th17 cells have been shown to promote cytotoxic T 
cell responses in a model of melanoma metastasis24, IL-17A has 
been found to favour tumour development in other models25–27. In 
fact, it has been previously reported that IL-17A boosts tumour devel-
opment by inducing a tumour-promoting microenvironment25 and 
that targeted deletion of IL-17A suppresses intestinal tumourigen-
esis26. Consistent with a pro-tumour function of IL-17A, it has also 
been reported that IL-17A expression is regulated by STAT3, a proto-
oncogene activated by IL-6 in tumour and tumour stromal cells, 
promoting tumour cell survival, proliferation and angiogenesis28,29. 
Moreover, IL-6 has been shown to be produced by tumour cell lines 
upon stimulation with IL-17A (ref. 27). Consistently, we found 
a significant upregulation of IL-6 mRNA expression in the tumour 
cell line L1C2 after stimulation with increasing doses of IL-17A 
(Fig. 4e). In contrast, protein analysis of TGF-β in the tumour cell 
supernatants showed a spontaneous release of TGF-β protein but 
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these baseline values were not significantly changed by application 
of IL-17A (Fig. 4f).
Taken together, these data suggested the presence of the Th17 
inducing cytokines IL-6 and TGF-β in the lung of L1C2-tumour-
bearing mice by T cell- and tumour cell-dependent sources.
T-bet-dependent proliferation of lung CD4 +  T cells in tumours. 
To further explore a potential relationship between Th17 and Treg 
cells in lung cancer in the presence and absence of T-bet, we ana-
lysed the influence of IL-17A on lung CD4 +  T cell proliferation in 
the tumour model. The potential relevance of this point is high-
lighted by the observation that Foxp3-expressing T regulatory cells 
are normally key suppressors of effector T cell proliferation30. 
We thus isolated lung CD4 +  T cells and analysed their proliferation 
after in vivo treatment either with recombinant IL-17A or with anti-
IL-17A antibody given intranasally. In vivo treatment with recom-
binant IL-17A (rc IL-17A) in this murine model of lung tumour 
significantly reduced and conversely, in vivo anti-IL-17A antibody 
treatment significantly increased, lung CD4 +  T cell proliferation 
ex vivo (Fig. 5a,b, respectively) in wild-type littermates. Moreover, 
in contrast to wild-type mice, we found that anti-IL-17A antibody 
treatment did not further augment proliferation of the already 
hyper-proliferating lung CD4 +  T cells in the T-bet-deficient mice 
bearing tumours (Fig. 5c).
Consistent with the increased immunosuppression in tumours, 
we detected increased numbers of GITR + CD4 + CD25 + Foxp3 +   
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T regulatory cells in the lungs of tumour-bearing mice. Local treat-
ment with recombinant IL-17A in vivo did not change the number 
of CD4 + CD25 + Foxp3 +  T regulatory cells, whereas conversely anti-
IL-17A antibody treatment suppressed the number of these cells 
in the lungs of wild-type mice as compared with the IgG-treated 
group (Fig. 6a). We then asked whether increasing concentrations 
of anti-IL-17A antibody would affect tumour growth. Although we 
did not notice any improvement in the tumour growth by increas-
ing twofold the doses of anti-IL-17A antibodies in vivo, we found 
a dose-dependent decrease in the number of tumour-associated 
CD4 + CD25 +  Foxp3 +  T regulatory cells after anti-IL-17A antibody 
treatment (Fig. 6b). These data suggest that there is already sufficient 
IL-17A production in vivo such that addition of exogenous IL-17A 
has no effect, whereas neutralization of IL-17A with anti-IL-17A 
antibodies has marked effects on regulatory T cells. Moreover, T-bet-
deficient mice bearing lung tumours showed an augmented number 
of CD4 + CD25 + Foxp3 +  T regulatory cells and an upregulation of 
IL-10, an immunosuppressive cytokine, in the supernatants of lung 
CD4 +  T cells compared with wild-type littermates in this tumour 
model (Fig. 6c,d, respectively). IL-6, a cytokine known to induce 
Th17 cells and suppress Foxp3-expressing cells, was increased in 
the supernatants of CD4 +  T cells isolated from the lung of tumour-
bearing T-bet-deficient mice (Fig. 6e). Moreover, IL-6 is a cytokine 
released by CD4 +  T cells producing IL-17A. Thus, the increase of 
IL-6 in the supernatants of lung CD4 +  T cells from T-bet-deficient 
mice supports a role for T-bet on the Th17 induction in this tumour 
model mediated by IL-6. Finally, the increased release of IL-17A by 
lung CD4 +  T cells isolated from the lung of T-bet-deficient mice 
bearing tumours could induce IL-6 production in tumour cells as 
demonstrated in vitro. To further examine this point, we analysed 
IL-6 production in tumour-bearing mice and found a significant 
induction of IL-6 mRNA in the lung of T-bet-deficient mice bear-
ing tumours as compared with the wild-type littermates indicating a 
role of IL-6 in lung carcinoma in T-bet-deficient mice (Fig. 6f).
IL-23/IL-23R levels in lung tumour and their dependence on 
T-bet. IL-23 is a tumour-inducing cytokine, released by antigen-
presenting cells, involved in the expansion of the Th17 pathway31–37. 
We thus looked at IL-23 and IL-23R mRNA levels in the lung. 
IL-23 levels were significantly higher in T-bet-deficient mice bearing 
tumours as compared with control wild-type mice (Fig. 7a). Fur-
thermore, IL-23R expression was not significantly different between 
lung CD4 +  T cells from wild-type mice and T-bet-deficient mice 
suggesting that these cells can respond to local IL-23 stimulation 
(Fig. 7b). These findings are consistent with the idea that the absence 
of T-bet favours a Th17 cytokine response in the lung via IL-23 in 
experimental lung tumours.
T-bet inhibits IL-17R levels in tumour-infiltrating CD4 +  T cells. 
We then hypothesized that the development of Th1 cells induced 
by anti-IL-17A antibody treatment might be explained by the pres-
ence of an IL-17A-mediated autocrine mechanism on CD4 +  T cells. 
Accordingly, we examined IL-17R expression on lung CD4 +  T cells 
in the presence and absence of the tumour. We found that lung 
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CD4 +  T cells do not co-express IL-17R when T-bet or Foxp3 are 
expressed (Fig. 7c,d, respectively). However, IL-17R was expressed 
on the surface of the tumour cell line L1C2 used to induce experi-
mental adenocarcinoma (Fig. 7e). Moreover, some CD4 +  T cells in 
the lung expressed the IL-17R and this receptor was upregulated in 
lung tumour-infiltrating CD4 +  and CD8 +  T cells of T-bet-deficient 
mice as compared with wild-type controls (Fig. 7f,g, respectively). 
Finally, in vivo anti-IL-17A antibody treatment resulted in reduc-
tion of IL-17R expression on the surface of tumour-infiltrating lung 
CD4 +  T cells (Fig. 7f) but not in CD8 +  T cells in the lungs of 
T-bet-deficient mice (Fig. 7g). Taken together, these data suggest that 
T-bet suppresses Th17 responses by inhibiting both IL-17A and 
IL-17R expression thus interfering with the autocrine and paracrine 
loops involved in the development of this pathway in CD4 +  T cells-
infiltrating lung tumours.
Discussion
Here we investigated the role of Th17 cells in tumours and their rela-
tionship with T-bet and Foxp3. We found an upregulation of the 
Th17 cell lineage associated with elevated Foxp3 levels in patients 
with lung adenocarcinoma. Furthermore, we demonstrated that 
targeting of IL-17A is beneficial in experimental lung cancer by 
inhibiting lung tumour-infiltrating T regulatory cells and induc-
ing IFN-γ-producing CD4 +  T cells in the presence of T-bet. Our 
findings suggest that IL-17A inhibitors could have broad clinical 
applications in lung cancer by inhibiting Th17 and T-regulatory cells 
in the presence of T-bet. Moreover, in the absence of T-bet, anti-
IL-17A antibody therapy could also be partly effective resulting in 
reduction of IL-17R expression on CD4 +  T cells and upregulation 
of IFN-γ-producing CD8 +  T cells with tumour killing function.
Although this experimental tumour model does not reflect vari-
ous characteristics of human lung cancer growth as compared with 
orthotopic transplantation models with human tissue in immuno-
compromised mice38,39, this approach permitted the analysis of 
antitumour T cell-mediated immune responses in mice with a nor-
mal immune system. Using this model we could demonstrate a key 
role for IL-17A in regulating tumour development in vivo.
Our studies in patients with lung adenocarcinoma revealed an 
inverse correlation between local T-bet and IL-17A levels. In addi-
tion, using the experimental lung adenocarcinoma model we uncov-
ered a major role for T-bet in regulating IL-23 and IL-17A levels 
in the lung. We found that IL-23 levels are significantly higher 
in lungs from T-bet-deficient mice bearing tumours as compared 
with wild-type controls suggesting that the tumour environment 
creates an IL-23-rich milieu favouring Th17 development. Further-
more, although it has been previously demonstrated that silencing 
of T-bet downregulates IL-23R expression in other experimental 
settings40, we found no difference in IL-23R mRNA levels between 
lung CD4 +  T cells from wild-type and T-bet-deficient mice sug-
gesting that T cells from the latter mice can respond to IL-23 in the 
lung. In any case, IL-17R-expressing CD4 +  T cells were significantly 
augmented in the lung of T-bet-deficient mice compared with con-
trols indicating a marked regulatory effect of T-bet on lung Th17 
cell development. Moreover, we reported here that the tumour cell 
line used for the in vivo studies produces cytokines favouring Th17 
cell development. In particular, this cell line spontaneously released 
TGF-β and produced IL-6 upon IL-17 stimulation, suggesting that 
in addition to T-bet levels in T cells, soluble factors produced by 
the tumour may control the local development of Th17 cells in lung 
adenocarcinoma.
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The i.n. administration of low doses of anti-IL-17A antibodies 
led to a significant suppression of tumour growth as compared with 
untreated and control IgG-treated mice suggesting a key functional 
role for IL-17A in controlling tumour growth in vivo. This observa-
tion was associated with marked changes in the composition and 
cytokine production of tumour infiltration T cells. In addition to 
effector T cells, changes in regulatory T cells were noted in the lung 
of tumour-bearing mice upon anti-IL-17A treatment. The Th17 lin-
eage of T lymphocytes has been thought to be in a reciprocal rela-
tionship with the development of CD4 + CD25 + Foxp3 +  T regula-
tory cells. In fact, the cytokine IL-6, together with TGF-β1 has been 
shown to favour Th17 development41,42, whereas it inhibits develop-
ment of T regulatory cells in vitro and in vivo. CD4 + CD25 + Foxp3 +  
T regulatory cells are known to suppress the immune responses 
against tumours, whereas the role of Th17 cells in lung tumours is 
not fully understood. Here, we found that the main transcription 
factors of human Th17 cells as well as the main transcription factor 
of T regulatory cells, Foxp3, were increased in lung tumour tissues 
obtained from patients with lung adenocarcinoma compared with 
control tissues indicating a dysregulation of these two T cell subsets 
in lung tumours, resulting in a parallel expansion of both local Th17 
and Treg responses. These findings suggested a potential direct rela-
tionship between both T cell lineages in lung cancer. This possibility 
could also be linked to the differentiation of inducible regulatory 
T cells36. Indeed, we demonstrated that anti-IL-17A antibody treat-
ment decreases the number of lung CD4 + CD25 + Foxp3 +  T cells in 
the presence of T-bet and resulted in amelioration of tumour growth 
in lung adenocarcinoma. This beneficial effect of anti-IL-17A anti-
body therapy was accompanied by decreased IL-6 levels and the 
presence of tumour-infiltrating lung CD4 +  T cells that released 
more IFN-γ and TNFα. These findings suggested that a key target of 
IL-17A are lung CD4 +  T cells, which express the IL-17R and inhibi-
tion of this interaction leads to decreased production of IL-6. These 
results are in agreement and extend the findings in other settings 
of tumours25,27. In fact, these authors described a tumour-inducing 
function of IL-17A and demonstrated that targeted deletion of IL-
17A in an IFN-γ-deficient background could ameliorate the tumour 
load. We further demonstrated that IL-17A is induced in T-bet-defi-
cient mice and might contribute to tumour growth by directly driv-
ing IL-6 production by tumour cells. In any case, the reduction of 
regulatory T cells upon anti-IL-17A antibody treatment is likely to 
be relevant for the control of tumour growth, as T regulatory cells 
have been demonstrated to have a pathogenic immunosuppressive 
role in the tumour43,44.
T-bet has been previously shown to control Th1 cytokine pro-
duction in autoimmunity45 and allergic asthma46. Furthermore, 
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T-bet regulates NK cell activity in melanoma20,21,47. The present 
findings using T-bet knockout mice and in vivo imaging of tumour 
growth in experimental lung cancer suggest that T-bet is a key regu-
lator of antitumour T cell responses and modulates Treg activity in 
lung cancer in vivo. We also showed that IL-17A-deficiency leads to 
increased IFN-γ levels in the airways confirming a reciprocal regu-
lation of Th1 and IL-17A levels in tumours also observed by oth-
ers27. In addition, we found that anti-IL-17A antibody treatment 
induced IFN-γ expression by CD8 +  T cells isolated from the lungs 
of T-bet-deficient mice as compared with those isolated from wild-
type littermates bearing tumours treated the same way. These data 
correlate with a previously reported distinct effect of T-bet in CD4 +  
and CD8 +  T cells48.
In conclusion, in experimental lung adenocarcinoma we demon-
strated that local blockade of IL-17A leads to suppression of tumour 
growth and an induction of IFN-γ production by CD4 +  T cells, 
while inhibiting lung CD4 + CD25 + Foxp3 +  T regulatory cells in the 
presence of T-bet. We further found that T-bet inversely correlated 
with IL-17A levels in patients with lung adenocarcinoma. Further-
more, the anti-IL-17A therapy in the absence of T-bet was partially 
effective and was associated with decreased IL-17R expression on 
CD4 +  and increased IFN-γ release by lung CD8 +  T cells, resulting 
in an increased survival of T-bet-deficient mice bearing tumours. 
Such an advantage should be considered for future tailored therapy 
in the absence of T-bet. Thus, anti-IL-17A antibody therapy emerges 
as an attractive approach for lung adenocarcinoma.
Methods
Human subjects and study population. Lung specimens were derived from the 
routine surgical pathology service in an anonymous fashion from the tumour tis-
sue bank of the program project (SFB432) supported by the Deutsche Forschungs-
gemeinschaft. The study was performed in agreement with the local ethics review 
board of Rheinland-Pfalz.
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Figure 7 | T-bet counteracts IL-17A via inhibition of IL-17R signalling on lung CD4 +  T cells. (a) qPCR analysis of IL-23 expression in wt (open column) 
and T-bet( − / − ) (filled column) total lung cells 21 days after injection of the tumour cell line L1C2 (N = 5 per group). (b) IL-23R expression in lung naive 
CD4 +  T cells of wt (open column) and T-bet( − / − ) (filled column) mice (N = 5 per group). (c) Flow cytometric analysis of IL-17R expression on CD4 +  
T-bet +  cells of naive and L1C2-tumour-bearing wt mice 21 days after injection of the tumour cells (N = 5 mice per group; representative of 3 independent 
experiments). (d) Flow cytometric analysis of IL-17R on CD4 + CD25 + Foxp3 +  T cells of naive and L1C2-tumour-bearing wt mice 21 days after injection of 
the tumour cells (N = 3–5 mice per group; representative of 3 independent experiments). (e) IL-17R expression on L1C2 tumour cells by flow cytometry 
(representative of three independent experiments). (f,g) Total lung cells isolated from naive and tumour-bearing wt (open columns) and T-bet( − / − ) 
(filled columns) mice untreated or treated with αIL17A antibody on day 5 and 8 were analysed 14 days after tumour cell injection. The number of CD4 + IL-
17R +  cells (f) and CD8 +  IL-17R +  lung cells is shown (N = 2–3 per group). Data are shown as mean values ± s.e.m. student’s two-tailed t-test was used. 
*P,0.05; **P,0.01; ***P,0.001.
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Quantitative Real-Time PCR in human samples. Total cellular RNA was extract-
ed from frozen tissue specimens using RNeasy Mini Kits (Qiagen). The resulting 
RNA (5 µg) was primed with a dT18 oligonucleotide and reverse transcribed with 
Superscript II (Invitrogen) according to the manufacturer’s instructions. Integrity 
of the obtained cDNA was tested by amplification of p53 transcripts in a 30-cycle  
PCR (sense, 5′-CGTGAGCGCTTCGAGATGTTCCG-3′; antisense, 5′-CCTAAC 
CAGCTGCCCAACTGTAG-3′; annealing temperature 67 °C). The individual 
gene-specific primer sets were designed to span exon/intron boundaries and 
quality controlled by PCR reactions using either DNA or not reverse transcribed 
RNA as template. For PCR analysis of individual gene transcripts, 0.5 µl first-strand 
cDNA was amplified with transcript-specific oligonucleotides (Operon), using 1 U 
Hot Star Taq DNA Polymerase (Qiagen) in a 30 µl reaction mixture, according to 
manufacturer’s instructions. The primer sequences and the respective annealing  
temperatures were as follows: HPRT (sense 5′-TGACACTGGCAAAACAAT 
GCA-3′; antisense 5′-GGTCCTTTTCACCAGCAAGCT-3′; annealing tempera-
ture 62 °C), RORα4 (sense 5′-TGTACTGATGTCAGCAGATCG-3′; antisense 
5′-ATGAAGTCGCACAATGTCTGG-3′; annealing temperature 60 °C), RORC2  
(sense 5′-AAAGCATCCTGGCAAAGCTGC-3′; antisense 5′-TCTTCCAGGT 
CACTTGGACAG-3′; annealing temperature 60 °C), IL-17A (sense 5′-TCACCTT 
GGAATCTCCACCGCA-3′; antisense 5′-GGCAGTGTGGAGGCTCCCTG-3′; an-
nealing temperature 60 °C), Foxp3 (sense 5′-CAAGGCTTCATCTGTGGCATC-3′; 
antisense 5′-CGTGTGAACCAGTGGTAGATC-3′; annealing temperature 60 °C)  
and T-bet (sense 5′-CCCTTGGTGTGGACTGAGAT-3′; antisense 5′-GTCGGT 
GTCCTCCAACCTAA-3′; annealing temperature 60 °C). Quantitative RT-PCR 
analysis was performed using the ABI PRISM 3700 Sequence Detection System 
instrument and software (Applied Biosystems) with the QuantiTect SYBR Green 
PCR Kit (Qiagen). Reactions were performed for 40 cycles in triplicates with 
specific primers (300 nM each) with initial denaturation/activation for 15 min at 
95 °C, 30 s denaturation at 95 °C, 30 s annealing, and 30 s amplification at 72 °C. 
The relative expression level of specific transcripts was calculated with respect to 
the internal standard, hypoxanthine-guanine-phosphoribosyltransferase (HPRT), 
to normalize for variances in the quality of RNA and the amount of input cDNA. 
Expression levels were normalized to normal lung tissues using ∆∆CT calculation. 
In each experiment, a template-free negative control was included.
Cells. The L1C2 (Line 1 alveolar cell carcinoma) adenocarcinoma cell line was cul-
tured in RPMI 1640 medium enriched with 10% fetal calf serum (FCS) (Biofluids) 
and 1% penicillin/streptavidin (Gibco, Invitrogen) antibiotics as previously de-
scribed47. Lewis lung carcinoma cell line (LLC1) was obtained from the American 
Type Culture Collection (ATCC), and cultured in DMEM with 10% FCS and 1% 
penicillin/streptavidin. Both cell lines were tested negative for mycoplasma and 
other transmissible infectious agents. The LL/2-luc-M38 Bioware Cell line (Caliper 
LifeSciences) was cultured in DMEM with 10% FCS and 1% penicillin/streptavidin.
Mice. BALB/cJ and C57/BL6 wild-type mice (6–12 weeks old) were maintained 
under specific pathogen-free conditions. T-bet( − / − ) mice were on a Balb/cJ genetic 
background. These mice were generously given to us by Professor L.H. Glim-
cher, Harvard Medical School (Boston, MA). IL-17( − / − ) mice were provided by 
Regeneron Pharmaceuticals on a C57BL/6 background. Wild-type littermates were 
used as controls. All experiments in mice were done under the licence number 
23177-07/G09-1-008 in Mainz and under the licence number IR5520301020 in 
Erlangen, Germany.
Murine model of lung adenocarcinoma and antibody treatment. For the ad-
enocarcinoma mouse model a total of 2×105 L1C2 cells (in 0.2 ml RPMI medium) 
were injected into the tail vein of BALB/cJ wt and T-bet( − / − )-mice49. In experi-
ments with wt and T-bet-deficient mice, mice were killed on day 14 after tumour 
cell injection. In experiments using BALB/cJ wt mice only, the animals were killed 
at day 21. Lungs were removed and analysed as described below. For the treatment 
with αIL17A antibody and recombinant IL-17A mice received 2×3 or 2×6 µg of 
anti-IL-17A (goat-anti-mouse antibody, R&D Systems) antibodies or control IgG 
antibody (goat IgG, R&D Systems) or 2×250 or 2×750 ng recombinant IL-17A 
(R&D Systems) in 50 µl PBS by i.n. application on days 5 and 8 or days 8 and 11 
after intravenous injection of L1C2 cells. For the Lewis lung carcinoma (LLC1) 
mouse model, 2.2×105 LLC1 cells, resuspended in DMEM without supplements,  
were injected into the tail vein of C57BL/6 wt and IL-17A-deficient mice.  
At day 21 the animals were killed and analysed.
Patho-histological analysis of the lungs. For histological analysis, lung samples 
were immersed in 10% buffered formalin before embedding in paraffin. Tumour 
load for each lung was quantified by a pathologist (H.-A.L). Three histological 
step sections were cut at 200 µm intervals from the paraffin block of each lung 
sample. The slides were stained with haematoxylin and eosin and examined using 
a diagnostic microscope for the presence of tumour foci. Tumour-containing slides 
were then photographed using a diagnostic microscope (Olympus BX45) and a 
digital camera (Olympus C4040) at ×4 magnification and imported as jpg files into 
Photoshop (Adobe Photoshop, version CS3). Using the pencil tool, the metastases 
were marked, the surface was covered by a tumour quantified using the histogram 
(number of pixels/total magnification), and set in relation to the surface covered 
by the lung (number of pixels/total magnification). Mean values were calculated 
for each lung based on the analysis of the three sections. In order to avoid observer 
bias, the morphometric analyses were performed while the pathologist was blinded 
to the group assignment of the lung samples.
Isolation of lung CD4 +  and CD8 +  T cells. Total lung cell suspension and CD4 + /
CD8 +  T lung cell isolation were performed as previously described50. Isolated  
T cells were cultured with plate-bound anti-CD3 antibody (CD3 clone 145-2C11, 
5 µg ml − 1) and soluble anti-CD28 antibody (CD28 clone 37.51, 2 µg ml − 1, BD 
Biosciences-PharMingen) for 20 h at a density of 106 cells ml − 1. Supernatants were 
collected, frozen and subsequently analysed for cytokine production by enzyme-
linked immunosorbent assay (ELISA).
FACS analysis and surface marker staining. Total lung cells (5×105) were 
washed with 1 ml PBS and incubated with 5 µg ml − 1 of different FACS anti-
bodies for 30 min at 4 °C. Afterwards the cells were washed with 1 ml PBS and 
measured by FACS Calibur and analysed by using Cell Quest Pro version 4.02 
(BD Biosciences) or by Flow-Jo 7.6 (Tree Star). The following anti-mouse FACS 
antibodies were used: CD4 PE or CD4 PerCP (BD Biosciences RM4-5), CD8a APC 
(BD Biosciences 53-6.7), IL-17R-FITC or IL-17R-PE (R&D Systems), CD25 PE 
(eBioscience PC61.5), and GITR-FITC (eBioscience DTA-1). To assure the purity 
of CD4 +  T cell isolation, anti-mouse CD4-APC antibody (L3T4 BD Biosciences) 
was used.
Intracellular staining. Freshly isolated total lung cells (1.5×106) were washed 
with 1 ml PBS, and incubated for 30 min at 4 °C with the surface FACS antibodies. 
After washing cells were fixed and permeabilized with Fixation/Permeabilization 
concentrate/diluent (eBioscience) and stained in 10× Permeabilization Buffer 
(eBioscience) for the intracellular proteins according to the manufacturer’s pro-
tocol. The following intracellular anti-mouse antibodies were used: Foxp3-APC 
(eBioscience FJK-16s) and T-bet-Alexa fluor 647 (eBioscience).
In-vitro analysis of lung CD4 +  cells. CD4 +  T cells were isolated from naive and 
tumour-bearing lungs 6 days after intravenous injection of 2×105 L1C2 cells. Lung 
CD4 +  T cells were then re-stimulated in-vitro with anti-CD3 antibody (5 µg ml − 1), 
anti-CD28 antibody (2 µg ml − 1), IL-2 (25 U ml − 1) and with either anti-IL-17A 
antibody (5 µg ml − 1) or IgG control for 3 days in culture. Afterwards IFN-γ was 
measured in the cell supernatant by ELISA.
ELISA. All cytokines in the supernatants were detected by specific sandwich ELISA 
sets. TNFα, IFN-γ, IL-10 and IL-6 ELISA sets (BD Biosciences), and IL-17A and 
TGFβ ELISA sets (R&D Systems) were used according to the manufacturer’s 
protocol.
Luciferase measurement. The luciferase-expressing LL/2-luc-M38 Bioware cell 
line (1 million cells per mouse per 200 µl) was injected in the tail vein of C57BL/6 
mice. At different time points the mice were injected intraperitonally with 150 µl 
luciferin (15 mg ml − 1), anaesthetised with isoflurane and luciferase activity was 
measured with the Caliper Ivis System by detecting the luminescence intensity to 
determine the tumour load in the lungs. The analysis was done in a logarithmic 
scale mode. For tumour load quantification the total flux (photons per second)  
was determined.
Tumour cell in vitro culture. The tumour cells (62.500 cells per ml) were cultured 
for 48 h with different concentrations of recombinant IL-17A (0–500 ng ml − 1) and 
αIL-17A antibody (1 µg ml − 1) (R&D systems). TGF-β levels in the supernatants 
were measured by ELISA as described above. Total RNA of the tumour cells was 
extracted and after cDNA synthesis (Fermentas) gene expression of the tumour 
cells was determined by qPCR (quantitative real-time PCR) using the following 
primers:
IL-6 fwd.: 5′-AGTTGCCTTCTTGGGACTGA-3′; IL-6 rev.: 5′-TCCACGATT 
TCCCAGAGAAC-3′.
Statistical analysis. Differences were evaluated for significance (P < 0.05) by the 
Student’s two-tailed t-test for independent events (Excel, PC). Where indicated 
statistical comparison was performed by using analysis of the variance. Data are 
given as mean values ± s.e.m. 
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